Clene (CLNN)
(Delayed Data from NSDQ)
$0.34 USD
-0.01 (-1.90%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.34 0.00 (0.03%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
0 items in cart
Clene Inc. [CLNN]
Reports for Purchase
Showing records 1 - 20 ( 89 total )
Company: Clene Inc.
Industry: Unclassified
Price: 25.00
Company: Clene Inc.
Industry: Unclassified
2023 Results; Collecting CNM-Au8 Data to Support Ongoing Regulatory Discussion For Potential NDA Submission in ALS
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 50.00
Company: Clene Inc.
Industry: Unclassified
4Q23: Seeking ALS Accel Approval NDA, But We Expect Phase 3, Cash Into 4Q24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Price: 25.00
Company: Clene Inc.
Industry: Unclassified
Disappointing Phase 3 Results From Competitor Reassure Difficulties to Meet Functional Primary Endpoints in ALS Trials
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 50.00
Company: Clene Inc.
Industry: Unclassified
Global Neurological Function Improvements Round Off VISIONARYMS OLE Data Package; CNM-Au8 Path Forward Updates Soon
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 25.00
Company: Clene Inc.
Industry: Unclassified
4Q23 Recap: Several Large Catalysts on Track For 2024 Though Some Uncertainties Persist
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 25.00
Company: Clene Inc.
Industry: Unclassified
Robust Vision and Cognition Improvements Following CNM-Au8 Treatment for 35 Months; Full VISIONARY-MS OLE Data in
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 25.00
Company: Clene Inc.
Industry: Unclassified
Price: 12.50
Company: Clene Inc.
Industry: Unclassified
Strong Updated Survival and Biomarker ALS Data; Regulatory Update Provides Visibility; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Clene Inc.
Industry: Unclassified
NfL Clinical Data Correlation in HEALEY Trial, But FDA Wants More Data
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Price: 12.50
Company: Clene Inc.
Industry: Unclassified
Price: 12.50
Company: Clene Inc.
Industry: Unclassified
3Q23: ALS Program Progresses Toward Regulatory Meetings, Funded Into 3Q24; $7 PT
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Price: 12.50
Company: Clene Inc.
Industry: Unclassified
3Q23 Results; CNM-Au8 Continues to Push Forward With ALS Regulatory Discussions in 4Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Clene Inc.
Industry: Unclassified
Helluva Financial Feather in the Cap; NIH Writing Big Checks; Data Support It
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Clene Inc.
Industry: Unclassified
Receives $45.1M, Four-Year NIH Grant for An EAP Evaluating CNM-Au8 in ALS
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Price: 5.00
Company: Clene Inc.
Industry: Unclassified
HEALEY Reveals Prolonged Survival Benefits in ALS; CNM-Au8 Path Forward and Regulatory Decisions Soon
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Clene Inc.
Industry: Unclassified
Unconventional Neuroprotective MoA and Favorable Clinical Evidence Back CNM-Au8 Path Forward; HEALEY OLE Data Soon
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Clene Inc.
Industry: Unclassified
Price: 12.50
Company: Clene Inc.
Industry: Unclassified
Significant RESCUE-ALS OLE Survival Benefit Delayed Clinical Worsening
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Price: 5.00
Company: Clene Inc.
Industry: Unclassified
No Rescuing of Thesis Needed Here; RESCUE-ALS Updated Data Impress
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50